Report      Database

    Adult Vaccines Market, Company Adult Vaccines Sales, Country Adult Vaccines - Worldwide Analysis - 2nd Edition

    Date: 06 Jul, 2017              Type: Vaccines              Pages: 181

    Adult Vaccines Market, Company Adult Vaccines Sales, Country Adult Vaccines - Worldwide Analysis - 2nd Edition
    • Electronic Access - Single User License
      $1,700.00
    • CD-ROM Mail Delivery
      $1,800.00
    • Hard-copy Mail Delivery
      $1,900.00
    • Electronic Access - Multi User License
      $2,500.00

    Get 10% Free Customization in this Report

    Adult Vaccines Market is expected to be close to US$ 20 Billion by the year 2022. Because of vaccines, some diseases (like Polio and Diphtheria) are becoming rare. Vaccination can prevent certain deadly diseases in all age groups. Almost all countries around the world have introduced efficient National Immunization Programme in their vaccination schedule to overcome the epidemics caused by vaccine-preventable diseases. WHO’s Global Vaccine Action Plan, Global Immunization Vision and Strategy (GIVS), The GAVI Alliance all are putting their best to minimize the incidence of vaccine-preventable diseases which indeed is driving the adult vaccine market vigorously.


    Influenza Vaccine Leads the Adult Vaccine Market for the Year 2017

    Influenza vaccine is dominating the adult vaccine segment in year 2017, however it will lose its place to Pneumococcal vaccine in the coming future as admissions for pneumonia had almost tripled over the last 15 years. Other than Influenza and Pneumococcal Vaccines, Cervical Cancer (HPV), Hepatitis and Travel vaccines also have considerable market share in adult vaccines market.


    Considerable Growth in Immunization of Cervical Cancer (HPV), Zoster, Meningococcal, Hepatitis, Tdap and MMRV Vaccines

    In terms of Immunization; Influenza holds the maximum share as influenza vaccination is recommended to take annually in almost all countries of the world. However, with the growing awareness and  efficiency of vaccines in preventing diseases, our analysis found that there will be considerably growth in the number for people opting for Cervical Cancer (HPV), Zoster, Meningococcal, Hepatitis, Tdap and MMRV vaccines in future till 2022.


    Administration of Vaccines Doses

    Influenza Vaccine holds the topmost place while talking about the administration of vaccine doses as influenza strains change every year and people needs to get an updated influenza shot each year to stay protected. Expect Influenza; Cervical Cancer (HPV), Pneumococcal and Hepatitis vaccines have remarkable administration doses.

    Adult Vaccines Market, Company Adult Vaccines Sales, Country Adult Vaccines - Worldwide Analysis is the 2nd publication by Renub Research on Adult Vaccines Market. This 181 pages research report with 77 Figures and 32 Tables provides a complete analysis of Adult Vaccines Market, Immunization Numbers in People, Number of Vaccine Doses Administered in Adults (Disease wise) & Key Players Analysis. 

     

    Adult Vaccines in the Report have been studied from 3 Viewpoints

    1.    Global Adult Vaccines (Disease wise) Market & Forecast (2011 – 2022)

    2.    People Immunized (Disease wise) & Forecast (2011 – 2022)

    3.    Doses of Vaccines Administered (Disease wise) & Forecast (2011 – 2022)


    9 Vaccines Studied in the Report are as Follows:

    1.    Influenza
    2.    Cervical Cancer
    3.    Zoster (Shingles)
    4.    MMRV (Measles, Mumps, Rubella and Varicella)
    5.    Pneumonia
    6.    Meningitis
    7.    Hepatitis
    8.    DTap (Diphtheria, Tetanus, Pertussis)
    9.    Travel & Miscellaneous Vaccine 

     

    Companies Vaccines Sales and Forecast 

    1. GlaxoSmithKline, plc Sales & Forecast (2011 – 2022)
    2. Merck & Co. Sales & Forecast (2011 – 2022)
    3. Sanofi Pasteur’s Sales & Forecast (2011 – 2022)
    4. Pfizer, Inc.’s Sales & Forecast (2011 – 2022)
    5. Others Vaccines


    Key Questions Answered In This Report

    •    What will be the Market Size of Global Adult Vaccine by the year 2022?

        What are the Key Drivers & Challenges for Adult Vaccines Market?

        Who are the key players in Adult Vaccine Market?

    •    What products are in key Players Pipeline?
     

    Content from Old Report is given below: 

    The user can buy this report in Chapters from Purchase by Chapter section given above  

    World Adult Vaccines Market – Market Overview
     
    For much of the 20th century, vaccines were a pharmaceutical success story largely associated with children. Aggressive immunization programs eradicated Polio and Smallpox among developed nations and nearly eliminated Mumps, Pertussis, Measles, and other diseases. While Pediatric Vaccines are an important market, it is now adults who are fueling growth of vaccine products. The world adult vaccines market is expected to nearly double by 2020 from the current figure of 2012. 
     
    Vaccination has played an enormous role in the prevention of disease, having had the greatest impact on human health of any medical intervention. As a result, vaccine preventable diseases and their resulting deaths are now rare in the developed world. However, the developing nations have not benefited as much from the introduction of vaccines. Additionally, other issues such as vaccine safety, shortages and bioterrorism continue to weigh upon the industry.
     
    Renub Research study titled “Adult Vaccines Market, Company Adult Vaccines Sales, Country Adult Vaccines - Worldwide Analysis” provides a comprehensive assessment of the fast-evolving, high-growth of World Adult Vaccines Landscape. This 222 page report with 142 Figures and 15 Tables studies: 9 Adult Vaccines Market, 5 Companies Adult Vaccines Sales. In total 28 Adult Vaccines have been researched for this report. This report is broadly divided into 11 chapters. 
     
    Adult Vaccines Market & Forecast data (2007 – 2020) covered in the report are as follows:
     
    1.  Influenza
    2.  Cervical Cancer/ HPV
    3.  Hepatitis
    4.  Zoster Shingles
    5.  Pneumococcal
    6.  Measles, Mumps, Rubella and Varicella (MMRV) 
    7.  Meningococcal
    8.  Diphtheria, Tetanus, Pertussis (DTP) 
    9.  Travel and Miscellaneous 
     
    Companies’ Adult Vaccines Sales Share and Forecast data (2007 – 2020) covered in the report
     
    1.  GlaxoSmithKline (GSK) 
    2.  Sanofi Pasteur 
    3.  Merck 
    4.  Novartis
    5.  Pfizer 
    6.  Others
     
    (Chapter 1): Executive Summary
     
    (Chapter 2): This Chapter is divided into 2 parts 
     
    A. Adult Vaccines Market and Forecast data from 2007 to 2020
     
    B. Adult Vaccinated Number and Forecast from 2007 to 2020
     
    (Chapter 3): This chapter is divided into 3 parts
     
    A. Provides market share (percentage) of Adult Vaccines in the above mentioned vaccines 
     
    B. Provides market share (percentage) of Adult Vaccinated in the above mentioned vaccines 
     
    C. Provides above mentioned companies market share in Adult vaccines. 
     
    (Chapter No. 4): This chapter is divided into 2 parts
     
    A. Companies given above Sales Share (percentage) in Disease Wise Break up & Forecast 
     
    B. Adult Vaccines given above Companies Share and Forecast 
     
    (Chapter 5): This chapter talks about all the 9 Adult Vaccines mentioned above. All these vaccines have been further sub-divided into 4 parts
     
    A. Adult Vaccine Market & Forecast 
     
    B. Number of Adults Being Vaccinated & Forecast
     
    C. Number of Adult Vaccines Doses & Forecast 
     
    D. Number of Cases 
     
    (Chapter 6): This chapter studies mentioned above all the 5 companies Adult Vaccines Sales and Forecast. The chapter further talks about the Company alliances with other Companies in order to increase their vaccine sales. 
     
    (Chapter 7): This chapter studies mentioned above all the 5 companies’ Sales and Forecast Disease Wise   
     
    (Chapter 8): This chapter provides Adult Vaccines Market and Forecast data of 8 Geographic Regions Worldwide.  
     
    1.  United States
    2.  North America/Caribbean 
    3.  South America 
    4.  Europe 
    5.  Japan 
    6.  India 
    7.  China 
    8.  Rest of the World (ROW) 
     
    (Chapter 9): This chapter comprises of important Mergers and Acquisitions happening in the field of vaccines
     
    (Chapter 10): This chapter studies growth Factors Driving the Adult Vaccines Market. In total 8 growth topics have been discussed in this chapter.  
     
    (Chapter 11): This chapter studies Challenges/Hindrances faced by Adult Vaccines Market. In total 7 challenges topics have been discussed in this chapter
      
     
    Data Sources
     
    This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by Renub Research team of industry experts.
     
    Primary sources include industry surveys and telephone interviews with industry experts. 
     
    Secondary sources information and data has been collected from various printable and non-printable sources like search engines, News websites, Government Websites, Trade Journals, White papers, Government Agencies, Magazines, Newspapers, Trade associations, Books, Industry Portals, Industry Associations and access to more than 500 paid databases. 

    1.    Research Findings

    2.    Global – Adult Vaccines Market and Forecast

    3.    Global – Adult Vaccines Market Share and Forecast

    4.    Worldwide – Adult Immunized Numbers and Forecast

    5.    Worldwide – Adult Immunized Share and Forecast

    6.    Worldwide – Doses of Adult Vaccines Administered and Forecast

    7.    Worldwide – Doses of Vaccines Administered to Adult Share and Forecast

    8.    Worldwide – Vaccine Companies Market Share and Forecast

    9.    Disease wise – Adult Vaccines Market and Forecast
    9.1    Influenza – Adult Vaccines Market and Forecast

    9.2    Cervical Cancer (HPV) – Vaccines Market and Forecast

    9.3    Zoster (Shingles) – Vaccines Market and Forecast

    9.4    MMRV (Measles, Mumps, Rubella, and Varicella Vaccine) – Adult Vaccines Market and Forecast

    9.5    Pneumococcal – Adult Vaccines Market and Forecast

    9.6    Meningococcal – Adult Vaccines Market and Forecast

    9.7    Hepatitis – Adult Vaccines Market and Forecast

    9.8    TdaP – Adult Vaccines Market and Forecast

    9.9    Travel and Miscellaneous – Vaccines Market and Forecast

    10.    Disease wise – Adult Immunized Numbers and Forecast
    10.1    Influenza – Number of Adults Immunized and Forecast

    10.2    Cervical Cancer (HPV) – People Immunized and Forecast

    10.3    Zoster (Shingles) – Number of People Immunized and Forecast

    10.4    MMRV – Number of Adults Immunized and Forecast

    10.5    Pneumococcal – Number of Adults Immunized and Forecast

    10.6    Meningococcal – Number of Adults Immunized and Forecast

    10.7    Hepatitis – Number of Adults Immunized and Forecast

    10.8    TdaP – Number of Adults Immunized and Forecast

    11.    Disease wise – Doses of Vaccines Administered and Forecast
    11.1    Influenza – Doses of Adult Vaccines Administered and Forecast

    11.2    Cervical Cancer (HPV) – Doses of Vaccines Administered and Forecast

    11.3    Zoster (Shingles) – Doses of Vaccines Administered and Forecast

    11.4    MMRV – Doses of Adult Vaccines Administered and Forecast

    11.5    Pneumococcal – Doses of Adult Vaccines Administered and Forecast

    11.6    Meningococcal – Doses of Adult Vaccines Administered and Forecast

    11.7    Hepatitis – Doses of Adult Vaccines Administered and Forecast

    11.8    TdaP – Doses of Adult Vaccines Administered and Forecast

    12.    Disease wise - Immunization Profile
    12.1    Immunization Coverage (%) in Infants (2005 – 2015)

    12.2    Global Immunization Profile (2011 – 2015)

    12.3    Regional Immunization Profile (2001 – 2015)
    12.3.1    Measles – Number of Cases Reported
    12.3.2    Mumps – Number of Cases Reported
    12.3.3    Rubella – Number of Cases Reported
    12.3.4    Rubella (CRS) – Number of Cases Reported
    12.3.5    Diphtheria – Number of Cases Reported
    12.3.6    Tetanus (Neonatal) – Number of Cases Reported
    12.3.7    Tetanus (Total) – Number of Cases Reported
    12.3.8    Pertussis – Number of Cases Reported
    12.3.9    Polio – Number of Cases Reported
    12.3.10    Yellow Fever – Number of Cases Reported
    12.3.11    Japanese encephalitis – Number of Cases Reported, 2006 - 2015

    13.    Vaccines Key Players Sales and Forecast
    13.1    GlaxoSmithKline, plc.’s Vaccines Sales and Forecast

    13.2    Merck & Co. Vaccines Sales and Forecast

    13.3    Sanofi Pasteur’s (France) Vaccines Sales and Forecast

    13.4    Pfizer, Inc.’s Vaccines Sales and Forecast

    13.5    Others Vaccines Sales and Forecast

    14.    Vaccines – Products and Pipeline
    14.1    GSK Vaccine Product Pipeline

    14.2    Merck Vaccine Product Pipeline

    14.3    Sanofi Vaccine Product Pipeline

    14.4    Pfizer Vaccine Product Pipeline

    15.    Top Mergers and Acquisitions in the Vaccine Industry

    16.    Vaccines and Regulator’s Interventions
    16.1    Making and Meeting Standards of Quality and Safety

    16.2    Vaccine Funding

    17.    Vaccine Market Drivers
    17.1    Inclusion in National Immunization Schedule

    17.2    Growing Immunization Coverage for HPV Vaccines

    17.3    Increase in Prevalence of Infectious Diseases

    17.4    Global Immunization Vision and Strategy (GIVS)

    17.5    GAVI Model Fuelling Vaccine Manufacturers
    17.5.1    The Partnership Model
    17.5.2    The Business Model

    17.6    Increasing Vaccine Availability in United States

    17.7    The Vaccine Safety Data link Project

    17.8    The Vaccine Injury Compensation Program

    17.9    Transforming of Vaccine Technologies

    17.10    Global Vaccine Action Plan by WHO (2011 - 2020)

    17.11    Continuous Focus on Effective Communication Strategies

    18.    Vaccines Market Challenges
    18.1    Hurdles to Optimal use of Licensed Vaccines
    18.1.1    Technical Obstacles
    18.1.2    Economic Obstacles
    18.1.3    Cultural Obstacles

    18.2    Complexity of Vaccine Development & Approval System Thwarts Product Development
    18.2.1    Legal Obstacles
    18.2.2    General Technical Barriers
    18.2.3    Economic Barriers
    18.2.4    Regulatory Barriers

    18.3    Shortening the Timeline for Vaccine Development

    18.4    Refusal/Resistance to Vaccination
    18.4.1    Vaccine Adverse Event Reporting System

    18.5    Vaccine Shortages and Delays

    18.6    Obstacles in Vaccine Research & Development

    18.7    Barriers to New Entrants in the Vaccines Market
     

     

    List of Figures

    Figure 2‑1: Worldwide – Adult Vaccines Market (Billion US$), 2011 – 2016
    Figure 2‑2: Worldwide – Forecast for Adult Vaccines Market (Billion US$), 2017 – 2022

    Figure 4‑1: Worldwide – Adult Immunized (Million), 2011 – 2016
    Figure 4‑2: Worldwide – Forecast for Adult Immunized (Million), 2017 – 2022

    Figure 6‑1: Worldwide – Doses of Adult Vaccines Administered (Million), 2011 - 2016
    Figure 6‑2: Worldwide – Forecast for Doses of Adult Vaccines Administered (Million), 2017 - 2022

    Figure 8‑1: Worldwide – Key Players Vaccines Market Share (Percent), 2011 - 2016
    Figure 8‑2: Worldwide – Forecast for Key Players Vaccines Market Share (Percent), 2017 - 2022

    Figure 9‑1: Influenza – Adult Vaccines Market (Billion US$), 2011 - 2016
    Figure 9‑2: Influenza – Forecast for Adult Vaccines Market (Billion US$), 2017 – 2022
    Figure 9‑3: Cervical Cancer (HPV) – Vaccines Market (Billion US$), 2011 – 2016
    Figure 9‑4: Cervical Cancer (HPV) – Forecast for Vaccines Market (Billion US$), 2017 - 2022
    Figure 9‑5: Zoster (Shingles) – Vaccines Market (Billion US$), 2011 - 2016
    Figure 9‑6: Zoster (Shingles) – Forecast for Vaccines Market (Billion US$), 2017 - 2022
    Figure 9‑7: MMRV – Adult Vaccines Market (Million US$), 2011 – 2016
    Figure 9‑8: MMRV – Forecast for Adult Vaccines Market (Million US$), 2017 – 2022
    Figure 9‑9: Pneumococcal – Adult Vaccines Market (Billion US$), 2011 - 2016
    Figure 9‑10: Pneumococcal – Forecast for Adult Vaccines Market (Billion US$), 2017 – 2022
    Figure 9‑11: Areas with frequent epidemics of meningococcal meningitis
    Figure 9‑12: Meningococcal – Adult Vaccines Market (Million US$), 2011 – 2016
    Figure 9‑13: Meningococcal – Forecast for Adult Vaccines Market (Million US$), 2017 - 2022
    Figure 9‑14: Hepatitis – Adult Vaccines Market (Billion US$), 2011 - 2016
    Figure 9‑15: Hepatitis – Forecast for Adult Vaccines Market (Billion US$), 2017 - 2022
    Figure 9‑16: TdaP – Adult Vaccines Market (Million US$), 2011 - 2016
    Figure 9‑17: TdaP – Forecast for Adult Vaccines Market (Million US$), 2017 - 2022
    Figure 9‑18: Travel and Miscellaneous – Vaccines Market (Billion US$), 2011 - 2016
    Figure 9‑19: Travel and Miscellaneous – Forecast for Vaccines Market (Billion US$), 2017 - 2022

    Figure 10‑1: Influenza – Number of Adults Immunized (Thousand), 2011 - 2016
    Figure 10‑2: Influenza – Forecast for Number of Adults Immunized (Thousand), 2017 - 2022
    Figure 10‑3: Cervical Cancer – Number of People Immunized (Thousand), 2011 - 2016
    Figure 10‑4: Cervical Cancer – Forecast for Number of People Immunized (Thousand), 2017 - 2022
    Figure 10‑5: Zoster (Shingles) – Number of People Immunized (Thousand), 2011 - 2016
    Figure 10‑6: Zoster (Shingles) – Forecast for Number of People Immunized (Thousand), 2017 - 2022
    Figure 10‑7: MMRV – Number of Adults Immunized (Thousand), 2011 - 2016
    Figure 10‑8: MMRV – Forecast for Number of Adults Immunized (Thousand), 2017 - 2022
    Figure 10‑9: Pneumococcal – Number of Adults Immunized (Thousand), 2011 - 2016
    Figure 10‑10: Pneumococcal – Forecast for Number of Adults Immunized (Thousand), 2017 - 2022
    Figure 10‑11: Meningococcal – Number of Adults Immunized (Thousand), 2011 - 2016
    Figure 10‑12: Meningococcal – Forecast for Number of Adults Immunized (Thousand), 2017 - 2022
    Figure 10‑13: Hepatitis – Number of Adults Immunized (Thousand), 2011 - 2016
    Figure 10‑14: Hepatitis – Forecast for Number of Adults Immunized (Thousand), 2017 - 2022
    Figure 10‑15: TdaP – Number of Adults Immunized (Thousand), 2011 - 2016
    Figure 10‑16: TdaP – Number of Adults Immunized (Thousand), 2017 - 2022

    Figure 11‑1: Influenza – Doses of Adult Vaccines Administered (Million), 2011 - 2016
    Figure 11‑2: Influenza – Forecast for Doses of Adult Vaccines Administered (Million), 2017 - 2022
    Figure 11‑3: Cervical Cancer (HPV) – Doses of Vaccines Administered (Million), 2011 - 2016
    Figure 11‑4: Cervical Cancer (HPV) – Forecast for Doses of Vaccines Administered (Million), 2017 - 2022
    Figure 11‑5: Zoster (Shingles) – Doses of Vaccines Administered (Million), 2011 - 2016
    Figure 11‑6: Zoster (Shingles) – Forecast for Doses of Vaccines Administered (Million), 2017 - 2022
    Figure 11‑7: MMRV – Doses of Adult Vaccines Administered (Million), 2011 - 2016
    Figure 11‑8: MMRV – Forecast for Doses of Adult Vaccines Administered (Million), 2017 - 2022
    Figure 11‑9: Pneumococcal – Doses of Adult Vaccines Administered (Million), 2011 - 2016
    Figure 11‑10: Pneumococcal – Forecast for Doses of Adult Vaccines Administered (Million), 2017 - 2022
    Figure 11‑11: Meningococcal – Doses of Adult Vaccines Administered (Million), 2011 - 2016
    Figure 11‑12: Meningococcal – Forecast for Doses of Adult Vaccines Administered (Million), 2017 - 2022
    Figure 11‑13: Hepatitis – Doses of Adult Vaccines Administered (Million), 2011 - 2016
    Figure 11‑14: Hepatitis – Forecast for Doses of Adult Vaccines Administered (Million), 2017 - 2022
    Figure 11‑15: TdaP – Doses of Adult Vaccines Administered (Million), 2011 - 2016
    Figure 11‑16: TdaP – Forecast for Doses of Adult Vaccines Administered (Million), 2017 - 2022

    Figure 12‑1: Worldwide Immunization Coverage (%) in Infants, 2005- 2010
    Figure 12‑2: Worldwide Immunization Coverage (%) in Infants, 2011- 2015

    Figure 13‑1: GlaxoSmithKline, plc.’s Vaccines Sales (Billion US$), 2011 - 2016
    Figure 13‑2: Forecast for GlaxoSmithKline, plc.’s Vaccines Sales (Billion US$), 2017 - 2022
    Figure 13‑3: Merck & Co. Vaccines Sales (Billion US$), 2011 - 2016
    Figure 13‑4: Forecast for Merck & Co. Vaccines Sales (Billion US$), 2017 - 2022
    Figure 13‑5: Sanofi Pasteur’s Vaccines Sales (Billion US$), 2011 - 2022
    Figure 13‑6: Forecast for Sanofi Pasteur’s Vaccines Sales (Billion US$), 2017 - 2022
    Figure 13‑7: Pfizer, Inc.’s Vaccines Sales (Billion US$), 2011 - 2016
    Figure 13‑8: Forecast for Pfizer, Inc.’s Vaccines Sales (Billion US$), 2017 - 2022
    Figure 13‑9: Others Vaccines Sales (Billion US$), 2011 - 2016
    Figure 13‑10: Forecast for Others Vaccines Sales (Billion US$), 2017 - 2022

    Figure 14‑1: GSK Vaccine Product Pipeline

    Figure 17‑1: Countries with HPV Vaccination Program listed on their National Immunization Program (NIP) Schedule
    Figure 17‑2: Number of Cases of Diphtheria, Pertussis, Tetnaus & Measles by Major Region Worldwide, 2013
    Figure 17‑3: Vaccines Procured by UNICEF: Industrialized and Emerging Market Country Manufacturers
    Figure 17‑4: Vaccines procured by UNICEF: Industrialized and Emerging Market Country Manufacturers
    Figure 17‑5: US Retail Clinics Expected to Surge by 2017

     

    Lists of Tables

    Table 2‑1: Vaccine Recommendations
    Table 2‑2: Other Recommended Vaccines

    Table 3‑1: Worldwide – Adult Vaccines Market Share (Percent), 2011 - 2016
    Table 3‑2: Worldwide – Adult Vaccines Market Share (Percent), 2017 - 2022

    Table 5‑1: Worldwide – Adult Immunized Share (Percent), 2011 - 2016
    Table 5‑2: Worldwide – Forecast for Adult Immunized Share (Percent), 2017 – 2022

    Table 7‑1: Worldwide – Doses of Vaccines Administered to Adult Share (Percent), 2011 - 2016
    Table 7‑2: Worldwide – Forecast for Doses of Vaccines Administered to Adult Share (Percent), 2017 - 2022

    Table 12‑1: Worldwide – Number of Reported Cases, 2011 – 2015
    Table 12‑2: Measles – Number of Cases Reported, 2001 – 2015
    Table 12‑3: Mumps – Number of Cases Reported, 2001 - 2015
    Table 12‑4: Rubella – Number of Cases Reported, 2001 - 2015
    Table 12‑5: Rubella (CRS) – Number of Cases Reported, 2001 - 2015
    Table 12‑6: Diphtheria – Number of Cases Reported, 2001 - 2015
    Table 12‑7: Tetanus (Neonatal) – Number of Cases Reported, 2001 – 2015
    Table 12‑8: Tetanus (Total) – Number of Cases Reported, 2001 - 2015
    Table 12‑9: Pertussis – Number of Cases Reported, 2001 - 2015
    Table 12‑10: Polio – Number of Cases Reported, 2001 - 2015
    Table 12‑11: Yellow Fever – Number of Cases Reported, 2001 - 2015
    Table 12‑12: Japanese encephalitis – Number of Cases Reported, 2006 - 2015

    Table 14‑1: Merck Vaccine Product Pipeline
    Table 14‑2: Sanofi Vaccine Product Pipeline
    Table 14‑3: Pfizer Vaccine Product Pipeline

    Table 15‑1: Vaccine Mergers & Acquisitions

    Table 17‑1: United States Immunization Schedule
    Table 17‑2: Afghanistan Immunization Schedule
    Table 17‑3: Norway Immunization Schedule
    Table 17‑4: India Immunization Schedule
    Table 17‑5: Vietnam Immunization Schedule
    Table 17‑6: Worldwide – Total Future Deaths Averted through Vaccination (Million), 2011 – 2020
    Table 17‑7: Goal-Level Indicators, 2015 & 2020
    Table 17‑8: Improvement Strategies or Requirements – the Joint Commission and the Project’s Collaborating Organizations

    • Description
      Price
    • Chapter 1 & 2     Pages : 26
      $300
    • Chapter 3     Pages : 7
      $300
    • Chapter 4     Pages : 17
      $300
    • Chapter 5.1     Pages : 6
      $200
    • Chapter 5.2     Pages : 8
      $200
    • Chapter 5.3     Pages : 5
      $200
    • Chapter 5.4     Pages : 7
      $200
    • Chapter 5.5     Pages : 5
      $200
    • Chapter 5.6     Pages : 8
      $200
    • Chapter 5.7     Pages : 9
      $200
    • Chapter 5.8     Pages : 9
      $200
    • Chapter 5.9     Pages : 2
      $200
    • Chapter 6     Pages : 23
      $200
    • Chapter 7     Pages : 30
      $200
    • Chapter 8      Pages : 16
      $200
    • Chapter 9     Pages : 3
      $200
    • Chapter 10     Pages : 12
      $200
    • Chapter 11     Pages : 13
      $200

    Related Products